David Lowe
Allergy & Immunology · Rochester, MNNPI 1770536062
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $15,373 of the $18,177 with a category attached, or 84.6%. Boehringer Ingelheim accounts for 93.6% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2019 at $13,583 and has fallen 97.5% since, to $344 in 2025. Among allergy & immunology clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 104 payments — averaging $174.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$17K
- Philips North America LLC$157
- AstraZeneca$124
- Amgen$120
- Regeneron Healthcare Solutions, Inc.$107
- Sanofi$82
- plus $569 from 16 others
What the payments were for
- Consulting fees$1431%
- Speaking & faculty fees$15,37385%
- Travel & lodging$9425%
- Food & beverage$1,6869%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 37 | $17,017 |
| Philips North America LLC | 5 | $157 |
| AstraZeneca | 8 | $124 |
| Amgen | 7 | $120 |
| Regeneron Healthcare Solutions, Inc. | 5 | $107 |
| Sanofi | 5 | $82 |
| Electromed, Inc. | 6 | $72 |
| Mylan Specialty L.p. | 3 | $52 |
| CSL Behring | 2 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $52 |
| Teva Pharmaceuticals USA, Inc. | 3 | $49 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $47 |
| Novartis | 3 | $47 |
| GSK | 2 | $36 |
| Alkermes, Inc. | 2 | $29 |
| ADMA Biomanufacturing LLC | 1 | $26 |
| Hospira, Inc. | 2 | $25 |
| Grifols USA, LLC | 2 | $24 |
| Advanced Respiratory, Inc | 1 | $20 |
| Endo Pharmaceuticals Inc. | 1 | $15 |
| Biocryst US Sales Co., LLC | 1 | $13 |
| Itamar Medical Inc | 1 | $12 |
How this compares
$18,177 in reported general payments places this provider in the 90th percentile of 57 allergy & immunology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 46 | $176,067 |
| Spiriva HandihalerTiotropium Bromide | 58 | $42,960 |
| XolairOmalizumab | 17 | $31,107 |
| Spiriva RespimatTiotropium Bromide | 49 | $30,709 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $24,773 |
| Breo ElliptaFluticasone/Vilanterol | 40 | $23,712 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $23,271 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 85 | $22,991 |
| DuleraMometasone/Formoterol | 52 | $21,517 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 31 | $21,005 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 20 | $18,029 |
| Incruse ElliptaUmeclidinium Bromide | 34 | $14,300 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 45 | $13,807 |
| SymbicortBudesonide/Formoterol Fumarate | 38 | $11,545 |
| TrulicityDulaglutide | 11 | $10,789 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat, Stiolto Respimat | $17,017 | $69,743100 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $36 | $62,78497 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $124 | $34,81764 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $52 | $4,27011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 57 allergy & immunology providers in Minnesota.
Other allergy & immunology in Rochester
- Thanai PongdeeRochester$58K
- Elina JerschowRochester$45K
- Dayne VoelkerRochester$8K
- Michael D'nettoRochester$2K
- Sergio ChiarellaRochester$1K
- Caitlin McNultyRochester$966
- Elizabeth EnderRochester$815
- Andrea SitekRochester$427
- Phillip LinkRochester$213
- James LiRochester$134
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.